Independent directors of the US company Systemix have rejected the unsolicited bid from Swiss pharmaceutical company Sandoz to acquire the outstanding stake it does not already hold in Systemix (Marketletters passim).
The decision taken by the directors, reports Reuters, was based in part on the advice from Lehman Brothers that the offer was inadequate and not fair to the minority shareholders.
Sandoz, which currently has a 73% stake in the US biotechnology company, has indicated its disappointment at the decision.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze